Claims
- 1. A method for inhibiting replication of reverse transcriptase dependent virus in animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus.
- 2. The method of claim 1, wherein said virus is a retrovirus.
- 3. The method of claim 1, wherein said deoxynucleoside phosphate depleting compound is a deoxynucleotide synthesis inhibitor.
- 4. The method of claim 1, wherein said deoxynucleoside phosphate depleting compound is an inhibitor of ribonucleotide reductase.
- 5. The method of claim 4, wherein said compound is hydroxyurea.
- 6. The method of claim 1, wherein said cells are in vitro.
- 7. The method of claim 1, wherein said animal cells are mammalian cells.
- 8. The method of claim 1 wherein said virus is the human immunodeficiency virus (HIV) and said cells are human cells.
- 9. A method for inhibiting replication of reverse transcriptase dependent virus in animal cells, comprising the steps of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate, in conjunction with administering to said cells an antiviral nucleoside phosphate analog.
- 10. The method of claim 9, wherein said deoxynucleotide phosphate depleting compound is an inhibitor of ribonucleotide reductase.
- 11. The method of claim 10, wherein said compound is hydroxyurea.
- 12. A method for inhibiting replication of reverse transcriptase dependent viruses in animal cells, comprising the steps of administering to said cells a first compound that depletes the intracellular pool of deoxyribonucleoside phosphate, in conjunction with a second compound that serves to inhibit replication of said virus by terminating DNA chain elongation.
- 13. The method of claim 12, wherein said second compound inhibits replication by premature termination of viral DNA synthesis to produce incomplete viral DNA.
- 14. The method of claim 12, wherein said first compound is an inhibitor of ribonucleotide reductase.
- 15. The method of claim 14, wherein said first compound is hydroxyurea.
- 16. The method of claim 15, wherein said second compound is selected from the group consisting of ddl, ddC, 2′-F-dd-ara-A, 2′-F-dd-ara-I and 2′-F-dd-ara-G.
- 17. The method of claim 12, wherein said second compound is selected from the group consisting of a dideoxynucleoside and AZT.
- 18. The method of claim 16, wherein said dideoxy nucleoside is a 2′-fluoro purine dideoxynucleoside.
- 19. The method of claim 16, wherein said dideoxynucleoside is selected from the group consisting of ddl, ddC, 2′-F-dd-ara-A, 2′-F-dd-ara-I and 2′-F-dd-ara-G.
- 20. A method of producing incomplete viral DNA from a reverse transcriptase dependent virus in animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of U.S. application Ser. No. 08/065,815, filed May 21, 1993.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09497770 |
Feb 2000 |
US |
Child |
09756411 |
Jan 2001 |
US |
Parent |
08245259 |
May 1994 |
US |
Child |
09497770 |
Feb 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08065815 |
May 1993 |
US |
Child |
08245259 |
May 1994 |
US |